Početna stranicaPRENW • NASDAQ
Prenetics
0,010 $
30. ruj, 14:20:26 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti
Zemlja u kojoj se trguje vrijednosnicom: SAD
Preth. zaklj. cijena
0,012 $
Dnevni raspon
0,010 $ - 0,012 $
Godišnji raspon
0,0042 $ - 0,060 $
Tržišna kapitalizacija
53,64 mil. USD
Prosječna količina
143,08 tis.
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD)ožu 2024.Godišnja promjena
Prihod
6,41 mil.−63,77 %
Operativni troškovi
12,94 mil.−35,05 %
Neto dohodak
−8,57 mil.21,92 %
Neto profitabilnost
−133,60−115,48 %
Zarada po dionici
EBITDA
−8,06 mil.25,95 %
Efektivna porezna stopa
3,07 %
Ukupna imovina
Ukupne obveze
(USD)ožu 2024.Godišnja promjena
Gotovinska i kratkoročna ulaganja
71,26 mil.−62,57 %
Ukupna imovina
243,59 mil.−16,31 %
Ukupne obveze
40,82 mil.−29,02 %
Ukupni kapital
202,76 mil.
Dionice u optjecaju
12,22 mil.
Cijena prema knjigovodstvenoj vrijednosti
0,00
Povrat imovine
−9,20 %
Povrat kapitala
−10,98 %
Neto promjena novca
(USD)ožu 2024.Godišnja promjena
Neto dohodak
−8,57 mil.21,92 %
Gotovina od poslovanja
Gotovina iz ulaganja
Gotovina iz financiranja
Neto promjena novca
Slobodan tok novca
Više
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Osnovano
2014
Web-lokacija
Zaposlenici
322
Pretraživanje
Izbriši pretraživanje
Zatvaranje pretraživanja
Googleove aplikacije
Glavni izbornik